![ISPOR Europe 2024 – May 5-8. Register now.]({"type":"image" , "src" : "/sda/112342/JournalAd-ISPOR-2024-Leaderboard.jpg"})
Citations (14)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (4)
Panagiotis Petrou. (2018) A systematic review of economic evaluations of tyrosine kinase inhibitors of vascular endothelial growth factor receptors, mammalian target of rapamycin inhibitors and programmed death-1 inhibitors in metastatic renal cell cancer. Expert Review of Pharmacoeconomics & Outcomes Research 18:3, pages 255-265.
Read now
Read now
Henry W. C. Leung, Agnes L. F. Chan, Chih-Hsin Muo & John Hang Leung. (2018) Cost-effectiveness of pertuzumab combined with trastuzumab and docetaxel as a first-line treatment for HER-2 positive metastatic breast cancer. Expert Review of Pharmacoeconomics & Outcomes Research 18:2, pages 207-213.
Read now
Read now
E Vrdoljak, L Torday, C Szczylik, G Kharkevich, S Bavbek & A Sella. (2016) Pharmacoeconomic and clinical implications of sequential therapy for metastatic renal cell carcinoma patients in Central and Eastern Europe. Expert Opinion on Pharmacotherapy 17:1, pages 93-104.
Read now
Read now
Feng Wen, Yu Yang, Pengfei Zhang, Jian Zhang, Jing Zhou, Ruilei Tang, Hongdou Chen, Hanrui Zheng, Ping Fu & Qiu Li. (2015) Cost-effectiveness of RAS screening before monoclonal antibodies therapy in metastatic colorectal cancer based on FIRE3 Study . Cancer Biology & Therapy 16:11, pages 1577-1584.
Read now
Read now
Articles from other publishers (10)
John Hang Leung, Yun-sheng Tai, Shyh-Yau Wang, Hei-Tung Yip Fion, Ho Tsung-chin & Agnes LF. Chan. (2022) Cost-effectiveness of trastuzumab biosimilar combination therapy and drug wastage as first-line treatment for HER2-positive metastatic breast cancer. The Breast 65, pages 91-97.
Crossref
Crossref
Qiaoping Xu, Li Yuanyuan, Zhu Jiejing, Liu Jian, Li Qingyu, Chen Lingya, Luo Ying, Shi Changchen, Li Yangling & Yan Wei. (2021) Cost-effectiveness of paclitaxel, doxorubicin, cyclophosphamide and trastuzumab versus docetaxel, cisplatin and trastuzumab in new adjuvant therapy of breast cancer in china. Cost Effectiveness and Resource Allocation 19:1.
Crossref
Crossref
Qiuji Wu, Xinyuan Wang, Mengxi Zhang, Weiting Liao, Feng Wang & Qiu Li. (2020) Cost-Effectiveness Analysis of Bevacizumab plus Paclitaxel versus Bevacizumab plus Capecitabine for HER2-Negative Locally Recurrent or Metastatic Breast Cancer. Oncology Research and Treatment 43:4, pages 153-159.
Crossref
Crossref
Feng Wen, Hanrui Zheng, Pengfei Zhang, Jing Zhou, Hongdou Chen, Kexun Zhou, Qiu Li & Feng Bi. (2019) Patient‐based cost‐effectiveness analysis of FOLFIRI versus FOLFOX7 for advanced gastric adenocarcinoma in China: A 4‐year prospective randomised phase II study. European Journal of Cancer Care 29:1.
Crossref
Crossref
Chun-Ru Chien, Daniel M. Geynisman, Bumyang Kim, Ying Xu & Ya-Chen Tina Shih. (2018) Economic Burden of Renal Cell Carcinoma—Part I: An Updated Review. PharmacoEconomics 37:3, pages 301-331.
Crossref
Crossref
Henry WC Leung, Agnes LF Chan & Shyh-Yau Wang. (2018) RETRACTED: Cost-utility analysis of trastuzumab combined with Docetaxel for patients with HER-2 positive metastatic breast cancer – real world claim data. Journal of Oncology Pharmacy Practice 24:6, pages NP2-NP8.
Crossref
Crossref
Steve J Edwards, Victoria Wakefield, Peter Cain, Charlotta Karner, Kayleigh Kew, Mariana Bacelar, Natalie Masento & Fatima Salih. (2018) Axitinib, cabozantinib, everolimus, nivolumab, sunitinib and best supportive care in previously treated renal cell carcinoma: a systematic review and economic evaluation. Health Technology Assessment 22:6, pages 1-278.
Crossref
Crossref
H.R. Zheng, F. Wen, Y.F. Wu, J.R.C. Wheeler & Q. Li. (2017) Cost-effectiveness analysis of additional docetaxel for metastatic hormone-sensitive prostate cancer treated with androgen-deprivation therapy from a Chinese perspective. European Journal of Cancer Care 26:6, pages e12505.
Crossref
Crossref
Mei Zhan, Hanrui Zheng, Ting Xu, Yu Yang & Qiu Li. (2017) Cost-effectiveness analysis of additional bevacizumab to pemetrexed plus cisplatin for malignant pleural mesothelioma based on the MAPS trial. Lung Cancer 110, pages 1-6.
Crossref
Crossref
Feng Wen, Hanrui Zheng, Yifan Wu, John Wheeler, Xiaoxi Zeng, Ping Fu & Qiu Li. (2016) Cost-effectiveness Analysis of Fluorouracil, Leucovorin, and Irinotecan versus Epirubicin, Cisplatin, and Capecitabine in Patients with Advanced Gastric Adenocarcinoma. Scientific Reports 6:1.
Crossref
Crossref